Akari Therapeutics PLC - ESG Rating & Company Profile powered by AI
Alternative companies in the scoring industry group for Akari Therapeutics PLC are displayedin the table. If you work at Akari Therapeutics PLC and you would like to licence your ESG rating, please get in touch. This webpage of Akari Therapeutics PLC is assembled by All Street Sevva using proprietary artificial intelligence.
Akari Therapeutics PLC in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 3.8; made up of an environmental score of 5.3, social score of 0.0 and governance score of 6.0.
3.8
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1089 | Zymeworks Inc | 3.9 | Medium |
| 1089 | bluebird bio Inc | 3.9 | Medium |
| 1112 | Akari Therapeutics PLC | 3.8 | Medium |
| 1112 | AcelRx Pharmaceuticals Inc | 3.8 | Medium |
| 1112 | Arcus Biosciences Inc | 3.8 | Medium |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Akari Therapeutics PLC have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Akari Therapeutics PLC disclose current and historical energy intensity?
Sign up for free to unlockDoes Akari Therapeutics PLC report the average age of the workforce?
Sign up for free to unlockDoes Akari Therapeutics PLC reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Akari Therapeutics PLC disclose its ethnicity pay gap?
Sign up for free to unlockDoes Akari Therapeutics PLC disclose cybersecurity risks?
Sign up for free to unlockDoes Akari Therapeutics PLC offer flexible work?
Sign up for free to unlockDoes Akari Therapeutics PLC have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Akari Therapeutics PLC disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Akari Therapeutics PLC conduct supply chain audits?
Sign up for free to unlockDoes Akari Therapeutics PLC disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Akari Therapeutics PLC conduct 360 degree staff reviews?
Sign up for free to unlockDoes Akari Therapeutics PLC disclose the individual responsible for D&I?
Sign up for free to unlockDoes Akari Therapeutics PLC disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Akari Therapeutics PLC disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Akari Therapeutics PLC disclose water use targets?
Sign up for free to unlockDoes Akari Therapeutics PLC have careers partnerships with academic institutions?
Sign up for free to unlockDid Akari Therapeutics PLC have a product recall in the last two years?
Sign up for free to unlockDoes Akari Therapeutics PLC disclose incidents of discrimination?
Sign up for free to unlockDoes Akari Therapeutics PLC allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Akari Therapeutics PLC issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Akari Therapeutics PLC disclose parental leave metrics?
Sign up for free to unlockDoes Akari Therapeutics PLC disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Akari Therapeutics PLC disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Akari Therapeutics PLC disclose the pay ratio of women to men?
Sign up for free to unlockDoes Akari Therapeutics PLC support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Akari Therapeutics PLC disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Akari Therapeutics PLC reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Akari Therapeutics PLC involved in embryonic stem cell research?
Sign up for free to unlockDoes Akari Therapeutics PLC disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Akari Therapeutics PLC disclose its waste policy?
Sign up for free to unlockDoes Akari Therapeutics PLC report according to TCFD requirements?
Sign up for free to unlockDoes Akari Therapeutics PLC disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Akari Therapeutics PLC disclose energy use targets?
Sign up for free to unlockDoes Akari Therapeutics PLC disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Akari Therapeutics PLC have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Akari Therapeutics PLC
These potential risks are based on the size, segment and geographies of the company.
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.